The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...